MicrobiotiX Completes Sentinel Cohort of its First-in-Human Clinical Trial of MP101 for Pneumonia

MicrobiotiX announced the successful completion of the sentinel cohort of its first-in-human Phase I clinical trial evaluating MP101 in patients with pneumonia caused by Pseudomonas aeruginosa.